Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Renovacor, Inc. (RCOR)

3.2   0.15 (4.92%) 11-30 16:00
Open: 3.04 Pre. Close: 3.05
High: 3.2 Low: 2.94
Volume: 14,313 Market Cap: 55(M)

Technical analysis

as of: 2022-12-06 8:20:56 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 3.93     One year: 4.59
Support: Support1: 2.58    Support2: 2.1
Resistance: Resistance1: 3.36    Resistance2: 3.93
Pivot: 2.98
Moving Average: MA(5): 3.06     MA(20): 2.92
MA(100): 2.31     MA(250): 3.7
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 83     %D(3): 75.6
RSI: RSI(14): 60.1
52-week: High: 9.73  Low: 1.34
Average Vol(K): 3-Month: 74 (K)  10-Days: 28 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RCOR ] has closed below upper band by 23.4%. Bollinger Bands are 43.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.2 - 3.22 3.22 - 3.24
Low: 2.96 - 2.98 2.98 - 3
Close: 3.17 - 3.2 3.2 - 3.23

Company Description

Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut.

Headline News

Thu, 01 Dec 2022
Rocket Pharmaceuticals Completes Acquisition of Renovacor - Business Wire

Mon, 28 Nov 2022
SHAREHOLDER ALERT: Contact the M&A Class Action Firm to Inquire about its Investigation of the Merger – SBCF, OYST, RCOR, SMBC - GlobeNewswire

Tue, 22 Nov 2022
Should Biotechnology Stock Renovacor Inc (RCOR) Be in Your Portfolio Tuesday? - InvestorsObserver

Sun, 20 Nov 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCOR, SMBC, TALO, BTRS - Renovacor (AMEX:RCOR), - Benzinga

Thu, 17 Nov 2022
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - OFIX, LMST, PFHD, RCOR - Benzinga

Tue, 15 Nov 2022
Should You Buy Renovacor Inc (RCOR) Stock on Tuesday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 17 (M)
Shares Float 6 (M)
% Held by Insiders 38.5 (%)
% Held by Institutions 57.5 (%)
Shares Short 224 (K)
Shares Short P.Month 215 (K)

Stock Financials

EPS -3.07
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.19
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.67
Qtrly Earnings Growth 0
Operating Cash Flow -10 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -1.05
PEG Ratio 0
Price to Book value 1
Price to Sales 0
Price to Cash Flow -5.33

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.